With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene ...

MacMaster, Ph.D., associate professor of Microbiology-Immunology, have discovered that administering an antibody treatment ...

Production tips from Crystal Bio, TriLink Biotechnologies, Ginkgo Bioworks, Quantoom Biosciences, and Parexel.